MicroRNA-492 expression promotes the progression of hepatic cancer by targeting PTEN

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Jiang, Jianxin ^a   Zhang, Yi ^a,b   Yu, Chao ^a   Li, Zhipeng ^a   Pan, Yaozheng ^a   Sun, Chengyi ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

AKT; Hepatocellular carcinoma; microRNA; PTEN

Indexed keywords

MICRORNA; MICRORNA 492; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PATHOGENESIS; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN TARGETING; SCID MOUSE; TUMOR CELL;

EID: 84908138114     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-014-0095-7     Document Type: Article

References (24)

1. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007, 23:175-205. 10.1146/annurev.cellbio.23.090506.123406, 17506695.
2. Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther J Am Soc Gene Therapy 2013, 21(5):986-994. 10.1038/mt.2013.35.
3. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22(7):894-907. 10.1101/gad.1640608, 18381893.
4. Lowery AJ, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer 2010, 10:502. 10.1186/1471-2407-10-502, 20858276.
5. Wang B, Hsu SH, Wang X, Kutay H, Bid HK, Yu J, Ganju RK, Jacob ST, Yuneva M, Ghoshal K. Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2. Hepatology 2014, 59(2):555-566. 10.1002/hep.26712, 24038073.
6. Wang L, Zhang X, Jia LT, Hu SJ, Zhao J, Yang JD, Wen WH, Wang Z, Wang T, Zhao J, Wang RA, Meng YL, Nie YZ, Dou KF, Chen SY, Yao LB, Fan DM, Zhang R, Yang AG. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology 2014, 59(5):1850-1863. 10.1002/hep.26720, 24002871.
7. Hong X, Liu Y, Hu G, Zhao D, Shen J, Shen F, Cao X, Wang Q. EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4 T1 murine mammary carcinoma. Cancer Sci 2009(5):961-969. 10.1111/j.1349-7006.2009.01129.x, 19445026.
8. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48(4):1312-1327. 10.1002/hep.22506, 18821591.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390. 10.1056/NEJMoa0708857, 18650514.
10. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441(7089):111-114. 10.1038/nature04688, 16565705.
11. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5(7):522-531. 10.1038/nrg1379, 15211354.
12. Braconi C, Patel T. Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr Cancer Drug Targets 2012, 12(9):1073-1080. 22873215.
13. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137(6):1005-1017. 10.1016/j.cell.2009.04.021, 19524505.
14. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007, 28(1):2-12. 10.1093/carcin/bgl185, 17028302.
15. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004, 14(10A):1902-1910. 10.1101/gr.2722704, 15364901.
16. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47(3):897-907. 10.1002/hep.22160, 18176954.
17. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25(17):2537-2545. 10.1038/sj.onc.1209283, 16331254.
18. Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, Cheuk AT, Smith MA, Houghton P, Morton C, Khan J. microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clinical Cancer Ees Off J Am Assoc Cancer Res 2009, 15(17):5560-5568. 10.1158/1078-0432.CCR-08-3287.
19. von Frowein J, Pagel P, Kappler R, von Schweinitz D, Roscher A, Schmid I. MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. Hepatology 2011, 53(3):833-842. 10.1002/hep.24125.
20. Kupcinskas J, Bruzaite I, Juzenas S, Gyvyte U, Jonaitis L, Kiudelis G, Skieceviciene J, Leja M, Pauzas H, Tamelis A, Pavalkis D, Kupcinskas L. Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer. Sci Reports 2014, 4:5993.
21. Buurman R, Gurlevik E, Schaffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kuhnel F, Skawran B. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 2012, 143(3):811-820. e811-815, 10.1053/j.gastro.2012.05.033, 22641068.
22. Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, Willenbring H, Dupuy A, Chen X, Brown D, Chang AN, Goga A. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1 /S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 2014, 59(1):202-215. 10.1002/hep.26662, 23913442.
23. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X, Wang Q. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol 2012, 188(11):5500-5510. 10.4049/jimmunol.1103505, 22544933.
24. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, Wiuf C, Sorensen FJ, Kruhoffer M, Laurberg S, Kauppinen S, Orntoft TF, Andersen CL. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008, 68(15):6416-6424. 10.1158/0008-5472.CAN-07-6110, 18676867.